Galectin Therapeutics (GALT) Shares Outstanding (2010 - 2026)

Galectin Therapeutics' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $65.9 million for Q1 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 4.05% year-over-year to $65.9 million in Q1 2026; TTM through Mar 2026 was $65.9 million, a 4.05% increase from a year earlier, with the FY2025 full-year figure at $65.2 million, up 3.24% from the prior year.
• Shares Outstanding (Entity) grew to $65.9 million in Q1 2026 per GALT's latest filing, from $65.2 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $65.9 million in Q1 2026 and bottomed at $59.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $62.1 million (2024), against an average of $62.0 million.
• Across the five-year window, Shares Outstanding (Entity) gained 0.14% in 2022 and gained 4.52% in 2024, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $59.4 million in 2022, then climbed by 4.08% to $61.9 million in 2023, then climbed by 2.11% to $63.2 million in 2024, then grew by 3.24% to $65.2 million in 2025, then grew by 1.0% to $65.9 million in 2026.
• Per Business Quant, the three latest GALT Shares Outstanding (Entity) figures stand at $65.9 million (Q1 2026), $65.2 million (Q4 2025), and $64.5 million (Q3 2025).